Dioseve Funding: ¥1B+ for iPS Cell Oocyte Maturation

Dioseve, a Japanese biotech innovator, has successfully closed a significant Series A extension funding round, bringing in over ¥1 billion (approximately $6.4 million USD). This capital infusion is earmarked to advance the commercialization of its groundbreaking in vitro maturation (IVM) technology for immature oocytes, utilizing induced pluripotent stem (iPS) cell-derived support cells.

The latest funding push saw robust participation from both existing and new investors. Archetype Ventures led the extension, joined by returning backers DG Daiwa Ventures and Miraidoor (Asuka Innovation Fund). The round also welcomed new strategic partners, including D4V, pharmaceutical giant Shionogi & Co., Ltd., and venture capital firm Pangaea Ventures. This brings Dioseve's total equity financing to ¥2.5 billion, further bolstered by ¥400 million in grant funding from the NEDO Deep Tech Startup Support Program (DTSU), totaling ¥2.9 billion.

At the heart of Dioseve's innovation is its proprietary product, codenamed ReproNest (DIOS-101). This system employs a co-culture methodology, where patient-derived immature oocytes are cultivated alongside specialized ovarian support cell-like cells derived from iPS cells. This approach aims to replicate the natural ovarian microenvironment, thereby enhancing oocyte maturation efficiency and potentially reducing the physical and emotional toll on patients undergoing fertility treatments. Crucially, ReproNest is designed as a culture system, not a cell therapy for direct administration.

The company's core technological advantage lies in its sophisticated differentiation induction platform. This platform enables the efficient generation of both oocytes and ovarian somatic cells from iPS cells, a critical step in producing the necessary ovarian support cells for the co-culture system. Early non-clinical studies suggest that this co-culture method offers a marked improvement over conventional IVM techniques in supporting the development of immature oocytes. The potential applications extend to fertility preservation for various patient groups, including those at high risk of ovarian hyperstimulation syndrome (OHSS) and individuals requiring rapid fertility preservation before commencing cancer therapies.

The newly acquired capital will be strategically deployed to accelerate the path to market for ReproNest. Key areas of focus include rigorous validation studies for practical application, refinement of manufacturing processes, comprehensive quality assessments, and ensuring batch-to-batch reproducibility. Furthermore, Dioseve will concentrate on establishing robust manufacturing and quality control systems, alongside advancing regulatory compliance efforts for both domestic and international markets. The company intends to leverage the NEDO DTSU program to support these crucial validation and system-building initiatives.

This funding round underscores the growing investor confidence in advanced reproductive technologies and the broader regenerative medicine sector. The market for fertility treatments and related innovations is experiencing substantial growth, driven by increasing awareness, delayed childbearing, and advancements in scientific capabilities. Dioseve's focus on improving IVM efficiency through iPS cell technology positions it to address significant unmet needs within assisted reproductive technology (ART), potentially offering a less burdensome and more effective solution for a growing patient population.